Generalized Myasthenia Gravis (gMG) is a condition that weakens your muscles. This study is a registry, meaning it’s a long-term collection of information about people with gMG who are receiving specific medicines called Alexion C5 Inhibition Therapies (C5ITs), like eculizumab (Soliris®) or ravulizumab (Ultomiris®). These therapies help to manage the symptoms of gMG. The study will look at how these medicines work and how safe they are over time. Information will be collected for up to 5 years using medical records and patient surveys. The study is open to people already being treated with these medicines and who have a history of gMG. However, if you are in another study for gMG treatments, you can’t join this one.

• The study lasts up to 5 years.
• Data will be collected during regular doctor visits.
• You must not be in another gMG treatment study to join.